Scholars Central

Conference abstractPublished 28 Sep 2015

Bioengineered Fusokine GIFT4 for cancer immunotherapy

Authors: Jiusheng Deng

Emory University School of Medicine, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Emerging evidences show immunotherapy by enhancing our own immune system has become an attractive approach for cancer treatment due to the rapid drug resistance of chemotherapy. Fusion cytokines derived from GM-CSF and common Ã?³-chain interleukins have potent gain-of-function properties to alter host immune response. Recently, we have generated a newly bioengineered fusokine GIFT4 that is derived from GM-CSF and IL-4, and tested the bioactivity of GIFT4 as a potential immunotherapeutic agent against caner. We observed that GIFT4 directly elicits anti-tumor adaptive B-cell immune response and consequent T cell immunity in vitro and in vivo. Murine GIFT4 expression suppresses melanoma tumor growth in immunologically intact mouse and administration of GIFT4 protein inhibits murine melanoma growth in vivo. GIFT4-B cell primed cytotoxic T cells from melanoma patients specifically kill human melanoma cells in vitro and in immune deficient NSG mice. Thus, GIFT4 defines a novel engineered cytokine that mediates endogenous expansion of B-cells with potent anti-tumor effector function. We propose that GIFT4 protein could serve as a novel immunotherapeutic agent and defines a previously unrecognized potential of B-cells for personalized cancer cell immunotherapy. We expect that GIFT4 as an anti-melanoma agent will provide a novel strategy and opens a new avenue for human B cell-based immunotherapy against melanoma. We propose that GIFT4-B cells could serve as a potent immunotherapeutic agent and define a previously unrecognized potential of B-cells for personalized cancer cell immunotherapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Jiusheng Deng”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels